Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors

被引:30
作者
Tsuda, N
Kato, N
Murayama, C
Narazaki, M
Yokawa, T
机构
[1] Nihon Schering KK, Yodogawa Ku, Preclin Dev Dept, Osaka 5320004, Japan
[2] Nihon Schering KK, Yodogawa Ku, Drug Discovery Inst, Osaka 5320004, Japan
关键词
MRI; contrast agent; hepatocellular carcinoma; animal;
D O I
10.1097/01.rli.0000105331.11373.c0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: To investigate whether dynamic and delayed magnetic resonance imaging (MRI) with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), a hepatobiliary MRI contrast agent, has potential for the differential diagnosis of experimental hepatic tumors. Methods: Twelve male rats received N-nitrosomorpholine solution as drinking water to induce hepatic tumors. After injection of Gd-EOB-DTPA, rats were subjected to dynamic and delayed MRI. The relative enhancement (RE) was calculated, and the time of the maximum RE (T-max) was evaluated. After MRI, liver was histologically analyzed. Results: One hundred sixty-three hepatic tumors 3-12 mm in diameter were induced after 18 weeks of treatment with 0.01 wt/vol% of N-nitrosomorpholine, and 81 of them were evaluated. The RE in hyperplastic nodules (HPNs) was significantly higher than that in moderately or poorly differentiated hepatocellular carcinomas (HCCs) in the late phase, whereas there was no significant difference in RE between well-differentiated HCCs and HPNs. The average T a in HPNs was about 13 minutes, whereas that of each differentiated HCCs was about 1 minute. Conclusions: It was possible to differentiate benign HPNs and malignant HCCs (especially well-differentiated HCCs) by evaluating the change of RE or comparison of T-max with Gd-EOB-DTPA-enhanced MRI.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 29 条
[21]  
2-B
[22]   Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: Preliminary results with dynamic MR imaging [J].
Reimer, P ;
Rummeny, EJ ;
Daldrup, HE ;
Hesse, T ;
Balzer, T ;
Tombach, B ;
Peters, PE .
EUROPEAN RADIOLOGY, 1997, 7 (02) :275-280
[23]   Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence [J].
Reimer, P ;
Rummeny, EJ ;
Shamsi, K ;
Balzer, T ;
Daldrup, HE ;
Tombach, B ;
Hesse, T ;
Berns, T ;
Peters, PE .
RADIOLOGY, 1996, 199 (01) :177-183
[24]   Effects of vitamins C and E on cytotoxicity induced by N-nitroso compounds, N-nitrosomorpholine and N-methyl-N′-nitro-N-nitrosoguanidine in Caco-2 and V79 cell lines. [J].
Robichová, S ;
Slamenová, D .
CANCER LETTERS, 2002, 182 (01) :11-18
[25]   Synthesis and physicochemical characterization of a new gadolinium chelate:: The liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA [J].
Schmitt-Willich, H ;
Brehm, M ;
Ewers, CLJ ;
Michl, G ;
Müller-Fahrnow, A ;
Petrov, O ;
Platzek, J ;
Radüchel, B ;
Sülzle, D .
INORGANIC CHEMISTRY, 1999, 38 (06) :1134-1144
[26]   Dynamic MR imaging of liver metastases with Gd-EOB-DTPA [J].
Stern, W ;
Schick, F ;
Kopp, AF ;
Reimer, P ;
Shamsi, K ;
Claussen, CD ;
Laniado, M .
ACTA RADIOLOGICA, 2000, 41 (03) :255-262
[27]  
Van Montfoort JE, 1999, J PHARMACOL EXP THER, V290, P153
[28]   A NEW LIPOPHILIC GADOLINIUM CHELATE AS A TISSUE-SPECIFIC CONTRAST-MEDIUM FOR MRI [J].
WEINMANN, HJ ;
SCHUHMANNGIAMPIERI, G ;
SCHMITTWILLICH, H ;
VOGLER, H ;
FRENZEL, T ;
GRIES, H .
MAGNETIC RESONANCE IN MEDICINE, 1991, 22 (02) :233-237
[29]   Transient peritumoral enhancement during dynamic MRI of the liver: Cavernous hemangioma versus hepatocellular carcinoma [J].
Yu, JS ;
Kim, KW ;
Park, MS ;
Yoon, SW .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2002, 26 (03) :411-417